Novo Nordisk Cuts Outlook As Wegovy Demand Slows
Wegovy momentum stalls as reality bites Novo Nordisk’s decision to slash its 2025 outlook represents a sobering reality check for the weight-loss drug market that had captured investor imagination. The company’s guidance cut from 13-21% sales growth to just 8-14% signals that the initial euphoria around GLP-1 medications may have been overdone. US Wegovy prescriptions […]